Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 12Fallopian Tube Neoplasms 6Breast Neoplasms 6Endometrial Neoplasms 4Prostatic Neoplasms 3Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Small Cell Lung Carcinoma 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Recurrence 1Neoplasm Metastasis 1Mesothelioma 1Fanconi Anemia, Complementation Group D1 1Colorectal Neoplasms 1Advanced Ovarian Cancer 1

Interventions

Saline Solution 3Carboplatin 2Bevacizumab 2talazoparib 1stenoparib 1senaparib 1sargramostim 1olaparib 1niraparib 1liposomal doxorubicin 1Tranexamic Acid 1Ropivacaine 1Paclitaxel 1Observation 1Neoadjuvant Therapy 1Hyperthermic Intraperitoneal Chemotherapy 1Antineoplastic Agents 11-dodecylpyridoxal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Ovarian Cancer × talazoparib × Gynecologic × Clear all
NCT01989546 2021-02-23

Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
9 enrolled 11 charts
BreastGynecologicOther solid neoplasm

Advanced Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡